CHARACTERIZATION OF LYMPHOBLAST PEPTIDE RECEPTORS
淋巴细胞肽受体的表征
基本信息
- 批准号:3182954
- 负责人:
- 金额:$ 17.43万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1987
- 资助国家:美国
- 起止时间:1987-09-30 至 1989-08-31
- 项目状态:已结题
- 来源:
- 关键词:aminoacid transport antibody receptor antineoplastics binding proteins cell differentiation cell growth regulation chromosome disorders cytogenetics electrofocusing flow cytometry gel electrophoresis gel filtration chromatography glucose transport hematopoietic stem cells hormone receptor immunofluorescence technique immunoprecipitation insulin insulin receptor insulinlike factor lymphoblast neoplasm /cancer therapy neoplastic growth peptide hormone phosphorylation radioimmunoassay radiotracer tissue /cell culture
项目摘要
In the past, we developed an assay which supports the growth of
malignant colonies from children with acute lymphoblastic
leukemia and non-Hodgkin's lymphoma. Our methodology differs
from in vitro culture techniques reported by others in that (albeit
sporadically) long term cell growth and cell line establishment
from passage of a single colony could be accomplished. Cell line
establishment, however, is important because cell lines provide an
unlimited, stable source of cells for in vitro studies. Cell lines
established in our laboratory have been shown to have the same
immunophenotype, biochemical enzyme profile, immunogenotype
and karyotype as the patient's tumor.
We have recently determined that different subtypes of malignant
lymphoblasts possess unique profiles for receptors to peptide
hormones. While each of 9 immature T-lymphoblast cell lines
possess IGF-I receptors and lack insulin receptors, 19 of 20
immature B-lymphoblast cell lines possess insulin receptors and
lack IGF-I receptors. We have shown that T-lymphoblasts
proliferate in response to nanogram concentrations of IGF-I but
not insulin in serum-free media. Moreover, supplemental IGF-I
has proven to be a key growth factor necessary in the
development of a reproducible, standardized method for the
establishment of T-lymphoblast cell lines in vitro. Based on these
data, we hypothesize that peptide hormones such as insulin and
IGF-I may be critical growth factors necessary for the
proliferation of malignant hematopoietic cells and that peptide
receptor function blockage may severely limit cellular
proliferation. The objective of this proposal is to study the
biologic function of specific peptides (I, IGF-I, IGF-II, CH) on
malignant hematopoietic cells which possess (or lack) specific
peptide receptors, and to determine the specificity, kinetics,
structure and function on specific peptide receptors by binding
studies, chemical cross-linking on SDS-PAGE, receptor
phosphorylation and by polyclonal and monoclonal antireceptor
antibodies. These studies will augment our understanding of
peptide/peptide receptor function in malignant cells, will help
establish standard methodologies for cell line establishment, and
may provide the foundation for antipeptide receptor therapy for
hematopoietic malignancies in the future.
在过去,我们开发了一种支持细胞生长的检测方法
儿童急性淋巴母细胞瘤的恶性集落
白血病和非霍奇金淋巴瘤。我们的方法不同
来自其他人报告的体外培养技术(尽管
零星地)长期细胞生长和细胞系的建立
从一个单一的蜂群通过可以完成。细胞系
然而,建立是重要的,因为细胞系提供了
为体外研究提供无限、稳定的细胞来源。细胞系
在我们实验室建立的已被证明具有相同的
免疫表型、生化酶谱、免疫表型
和核型作为患者的肿瘤。
我们最近确定了不同的恶性亚型
淋巴母细胞具有独特的多肽受体特征
荷尔蒙。而9个未成熟的T淋巴母细胞系
拥有IGF-I受体和缺乏胰岛素受体,20人中有19人
未成熟的B淋巴母细胞系具有胰岛素受体和
缺乏IGF-I受体。我们已经证明T淋巴母细胞
对纳克浓度的IGF-I有反应的增殖
而不是无血清介质中的胰岛素。此外,补充IGF-I
已被证明是关键的增长因素
开发一种可重复性的、标准化的方法
T淋巴母细胞系的体外建立基于这些
数据,我们假设多肽激素如胰岛素和
IGF-I可能是血管生成所必需的关键生长因子
恶性造血细胞及其多肽的增殖
受体功能阻断可能严重限制细胞
扩散。这项建议的目的是研究
特异性多肽(I、IGF-I、IGF-II、CH)的生物学功能
具有(或缺乏)特异性的恶性造血细胞
多肽受体,并确定其特异性,动力学,
结合的特异性多肽受体的结构和功能
研究,化学交联在十二烷基硫酸钠-聚丙烯酰胺凝胶上,受体
多克隆和单抗受体的磷酸化
抗体。这些研究将加深我们对
肿瘤细胞中的多肽/多肽受体功能,将有助于
建立建立细胞系的标准方法,以及
可能为抗肽受体治疗提供基础。
未来的恶性血液病。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
STEPHEN D SMITH其他文献
STEPHEN D SMITH的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('STEPHEN D SMITH', 18)}}的其他基金
CORRELATING MULTIPLE LABELING WITH ARRAY TOMOGRAPHY AND ELECTRON TOMOGRAPHY
将多重标记与阵列断层扫描和电子断层扫描相关联
- 批准号:
8169627 - 财政年份:2010
- 资助金额:
$ 17.43万 - 项目类别:
CORRELATING MULTIPLE LABELING WITH ARRAY TOMOGRAPHY AND ELECTRON TOMOGRAPHY
将多重标记与阵列断层扫描和电子断层扫描相关联
- 批准号:
7957638 - 财政年份:2009
- 资助金额:
$ 17.43万 - 项目类别:
CORRELATING MULTIPLE LABELING WITH ARRAY TOMOGRAPHY AND ELECTRON TOMOGRAPHY
将多重标记与阵列断层扫描和电子断层扫描相关联
- 批准号:
7722475 - 财政年份:2008
- 资助金额:
$ 17.43万 - 项目类别:
相似海外基金
Study on the mechanism of prolonged half-life of blood IgY by unique antibody receptor and its application to immune enhancement in birds
独特抗体受体延长血液IgY半衰期的机制研究及其在禽类免疫增强中的应用
- 批准号:
23H02361 - 财政年份:2023
- 资助金额:
$ 17.43万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Innate immune functions of the intracellular antibody receptor TRIM21
细胞内抗体受体 TRIM21 的先天免疫功能
- 批准号:
nhmrc : GNT1124162 - 财政年份:2017
- 资助金额:
$ 17.43万 - 项目类别:
Early Career Fellowships
Innate immune functions of the intracellular antibody receptor TRIM21
细胞内抗体受体 TRIM21 的先天免疫功能
- 批准号:
nhmrc : 1124162 - 财政年份:2017
- 资助金额:
$ 17.43万 - 项目类别:
Early Career Fellowships
Mechanism and engineering of IgG-based monoclonal antibody/receptor interactions
基于 IgG 的单克隆抗体/受体相互作用的机制和工程
- 批准号:
9300976 - 财政年份:2015
- 资助金额:
$ 17.43万 - 项目类别:
Mechanism and engineering of IgG-based monoclonal antibody/receptor interactions
基于 IgG 的单克隆抗体/受体相互作用的机制和工程
- 批准号:
9920805 - 财政年份:2015
- 资助金额:
$ 17.43万 - 项目类别:
Augmenting Chimeric Antibody Receptor Directed T cell Therapy for Cancer
增强嵌合抗体受体定向 T 细胞治疗癌症
- 批准号:
8900121 - 财政年份:2012
- 资助金额:
$ 17.43万 - 项目类别:
Augmenting Chimeric Antibody Receptor Directed T cell Therapy for Cancer
增强嵌合抗体受体定向 T 细胞治疗癌症
- 批准号:
8225814 - 财政年份:2012
- 资助金额:
$ 17.43万 - 项目类别:
Augmenting Chimeric Antibody Receptor Directed T cell Therapy for Cancer
增强嵌合抗体受体定向 T 细胞治疗癌症
- 批准号:
8699511 - 财政年份:2012
- 资助金额:
$ 17.43万 - 项目类别:
Augmenting Chimeric Antibody Receptor Directed T cell Therapy for Cancer
增强嵌合抗体受体定向 T 细胞治疗癌症
- 批准号:
8525355 - 财政年份:2012
- 资助金额:
$ 17.43万 - 项目类别:
Small Grants for Exploratory Research: Separation of Cells and Biological Macromolecules by Antibody Receptor Coated Magnetic Vesicles and Ferritin Conjugates
探索性研究小额资助:通过抗体受体包被的磁囊和铁蛋白缀合物分离细胞和生物大分子
- 批准号:
9115537 - 财政年份:1991
- 资助金额:
$ 17.43万 - 项目类别:
Standard Grant














{{item.name}}会员




